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Abstract

As a 5-α reductase inhibitor, Finasteride has proven effective in ameliorating two
conditions documented to be androgen dependent, namely male androgenic alopecia and
benign prostatic hyperplasia. Therapeutic results are maintained as long as the drug is
administered, with treatment cessation generally leading to the return of symptomatology
for each condition. In addition, during the therapeutic phase, several adverse effects have
been reported, some of which persist long or indefinitely after treatment cessation, known as
“post-finasteride syndrome.”
Herein we present and discuss the most common finasteride side effects, along with a
psycho-neuroendocrine rationale that could explain the persistence of many adverse effects
after treatment cessation. Moreover, we argue that finasteride adverse effects occurring
during finasteride administration should be delineated from postfinasteride side effects
(encountered after treatment cessation), suggesting the need to be addressed separately
within a therapeutic perspective. Until a tailored therapeutic approach of postfinasteride
syndrome becomes available, we have noted that hand preference and sexual orientation
seem to be useful as possible predicting factors for finasteride side effects and
postfinasteride syndrome.
Finally, even though finasteride administration is considered relatively safe, literature
data urges prudence. Specifically, recent studies report that some subjects receiving
finasteride develop severe depressive episodes including suicidal thoughts, in part due to
persistent sexual side effects.

Keywords: finasteride, adverse effects, post-finasteride syndrome, mental disorders,
sexual dysfunctions

Corresponding author: Ion G. Motofei MD., PhD., Carol Davila University, Department of Surgery and Urology
e-mail: igmotofei@yahoo.com

David L. Rowland. et al.

Introduction

approaches being intended to address the specific

Finasteride is an extensively used medication
for treatment of male pattern hair loss and benign
prostatic hyperplasia. It is a type II and type III

signs and symptoms rather than taking the approach
of addressing the issue as a broader neuroendocrine disorder (9).

inhibitor of 5-α reductase, an enzyme that converts Discussion
testosterone, progesterone and deoxycorticosterone
Male androgenic alopecia is a moderately
to their corresponding metabolites. Even though
stressful condition that often warrants medical
therapeutic efficacy has been demonstrated through
treatment, due to alteration of body image
several studies, the research literature describes
satisfaction. Benign prostatic hyperplasia (BPH/
multiple adverse effects occurring during
benign enlargement of the prostate) is a relatively
therapeutic phase (1, 2). Moreover, for some
common condition in elderly men, being
subjects, these effects have been described as “postrepresented by a variable increase in volume of the
finasteride” syndrome, consisting in signs and
prostate through prostatic hyperplasia. Both
symptoms that continue after treatment cessation (at
three months or more) and that are related conditions are closely related to/ favored by action
particularly to mental and sexual side effects of dihydrotestosterone (DHTT). As a consequence,
(depression, anxiety, suicidal thoughts, erectile and compounds interfering with DHTT synthesis
orgasmic troubles, etc.) (3). Other adverse effects of (finasteride, dutasteride) have been investigated and
postfinasteride syndrome are represented mostly by introduced in clinical practice as therapeutic
physical impairments, consisting in gynecomastia, possibilities for these two conditions (10, 11).
chronic fatigue, increased fat deposition, secondary

Therapeutic approaches

infertility, etc (4, 5).

Finasteride

Testosterone,

progesterone,

was

initially

approved

for

deoxycortico- treatment of benign prostatic hyperplasia; five years

sterone (and their corresponding metabolites) act as later it was recognized for the second indication as
neurosteroids within the brain, being at least in part a therapeutic approach for male androgenic alopecia
responsible

for

finasteride

side

effects

and (12).

postfinasteride syndrome (6). Taking into account

Regarding

benign

prostatic

hyperplasia,

that cerebral activation through neurosteroids is physicians usually prescribe 5 mg finasteride/day,
generally related to lateralized process of the brain, which has proven effective in ameliorating specific
finasteride adverse effects actually demonstrate a symptoms related to prostate enlargement, such as
predictability related to hand preference and sexual night time and difficult urination (decreased flow,
orientation (7, 8). Regarding the therapeutic prolonged initiation etc.). These positive effects can
approach to postfinasteride syndrome, no specific be obtained after six months or more from
therapy is yet agreed upon or recommended, current finasteride

administration;

however,

these
100
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therapeutic results typically cease after finasteride 95- 99% (17). In addition to inhibition of type II
and III of 5-α reductase isoenzymes, finasteride

cessation (at variable periods of time) (13).

Regarding androgenic alopecia, finasteride is inhibits type II of the 5β-reductase isoenzyme,
recommended only in men. It is not approved for which also interferes in androgen metabolism (18).
use in women due to risks of birth defects in the In humans, the 5a reductase isoenzymes are
fetus. At a dose of 1 mg/ day, finasteride provides encountered in several tissues including brain,
up to 20-30% improvement in hair loss after about prostate, skin/ hair follicles, liver, seminal vesicles,
six months of treatment. However, as in the case of testicles, and gastrointestinal tract (19).
benign prostatic hyperplasia, therapeutic benefits

Centrally, DHTT intervenes in metabolism of

are maintained only so long as the drug is testosterone, progesterone and deoxycorticosterone,
administered (14).
Thus,

known as active neurosteroids able to interfere with

therapeutic

recommendations

of the activation of the GABAA receptors in the brain

finasteride imply administration of the drug for a (20).

Hormonal

abnormalities

and

GABA

considerable period of time (six months or more, to disruption induced by Finasteride administration are
become effective), for both benign prostatic encountered in formerly-treated patients as well.
hyperplasia and androgenic alopecia. During this Such men exhibit (at variable periods of time after
prolonged

period,

several

neuroendocrine the therapy) persistent disturbed levels of several

imbalances occur, which form the basis for active neurosteroids in cerebrospinal fluid and
finasteride and postfinasteride adverse effects.

plasma: increased testosterone, 5a-androstane-3a,

Pharmacology

17b-diol,

pregnenolone,

Finasteride is a type II and type III inhibitor of dihydrotestosterone,

and

decreased

progesterone,

dihydropro-

5-α reductase, an enzyme that converts testosterone, gesterone and allopregnanolone (21).
progesterone and deoxycorticosterone to their

Adverse effects

corresponding

The cerebral actions of finasteride (via

metabolites,

dihydrotestosterone,

represented

dihydroprogesterone,

by

and hormones and GABA transmission) are usually

dihydrodeoxycorticosterone respectively. Due to responsible for most finasteride adverse effects,
this action, the serum level of DHTT decreases after while peripheral effects (reducing androgen activity
administration of 1 mg/day finasteride by about 65– in the scalp and prostate) are responsible for its
70%, and up to 85–90% after 5 mg/ day finasteride therapeutic action. Regarding finasteride side
administration (15, 16). Finasteride does not effects, these manifestations are the consequence of
completely suppress 5-α reductase and DHTT indirect actions of the drug within the brain
synthesis, in contrast to dutasteride that, by (through hormonal imbalances, GABA, and other
inhibiting all three isoforms of 5α-reductase possible/ unknown mechanisms) that add to other
enzyme, decreases the DHTT plasmatic level up to adverse effects resulting from the direct action of
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finasteride on the brain and peripheral organs prostate cancers) is due to DHTT decreasing, yet
(nausea, vomiting, allergies, etc.) (22).
Hormonal

abnormalities

finasteride administration is associated to a greater

and

GABA extent with high-grade prostate cancers (which

imbalances induced by Finasteride are encountered seem unrelated in its progression to androgens) (26,
in some patients after the therapy as persistent 27). In addition, finasteride lowers the PSA
neuroendocrine disorders. As a consequence, (prostate-specific antigen), which can be a serious
finasteride side effects (as clinical expression of impediment to the early detection of the prostate
neuroendocrine disorders) are also encountered cancer (28). Although the incidence of male breast
after drug discontinuation, in the form of so-called cancer has not increased from clinical trials (after 5
post-finasteride syndrome. The most frequent mg finasteride, daily), there have been case reports
manifestations of post-finasteride syndrome are of breast cancer in men taking finasteride. Yet,
represented by sexual disorders (impotence, erectile studies indicate no causative relationship between
dysfunction, decreased libido, ejaculation disorders) finasteride administration and male breast cancer
and mental/psychological impairments (depression, (29, 30). Preliminary studies on women show that
suicidal ideations, anhedonia, lack of mental 5-α reductase inhibitors induce sexual side effects
concentration, etc.) (23). Other less common also in women, even if this was reported in a lower
adverse effects are represented by: insomnia, extent (31).
premenstrual and postpartum dysphoric disorder,

The persistence of adverse effects

catamenial

As

epilepsy,

physical

impairments

noted

above,

the

most

frequent

(gynecomastia/ female-like enlargement of the manifestations of post-finasteride syndrome are
breast, chronic fatigue, muscle twitching and represented by sexual disorders and mental
atrophy, decreased body temperature, increased fat impairments.
deposition/

elevated

cardiovascular

body

mass

impairments

index),

Multiple

interrelations

exist

between

(palpitations, cognition and sexuality, due to the fact that both

hypotension), dermatologic and oral manifestations functions arise from the same set of environmental
(chronically dry, pruritus, rash, urticaria, erythema, stimuli, peripherally sharing common somatic
purpura, gingival hypertrophy) (24). In addition, afferents as well as centrally sharing a common/
finasteride administration may affect tolerance to mental operator for environmental tasks (32, 33).
ethanol, with many former users of finasteride These
noting

decreased

tolerance

for

alcohol

psychophysiologic/

neuroendocrine

and interrelations between cognition and sexuality are

disturbing effects from alcohol consumption (some bidirectional such that, when are disturbed, they
men cease drinking completely) (25).

often

generate

a

vicious

neuro-endocrine

Finally, reducing the risk of prostate cancers reciprocating process (between depression for
dependent

on

androgens

(namely

low-grade example, and sexual dysfunctions), with each being
102
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able to maintain or to intensify the other (34). pheromones have an impact on heterosexual men
According to several studies, the postfinasteride (opposite orientation), activating in particular the
syndrome is irreversible in some patients (35, 36).

right hemibrain, that is, the opposite hemisphere,

Such looped mechanism could perhaps explain including right hippocampus, right amygdala, right
the persistence of finasteride side effects in the form parahippocampal gyrus, etc.) (42- 44).
of

postfinasteride

syndrome.

Due

to

such

bidirectional interferences, depression and sexual
dysfunctions seem to be frequently associated, not
only after finasteride administration but also in a
multitude of other distinct situations (34, 37, 38).
The lateralized process of finasteride, in respect

The levels of dihydrotestosterone, dihydro-

decrease

and

substantially

dihydrodeoxycorticosterone
in

all

men

that finasteride adverse effects might be correlated
with both hand preference and sexual orientation of
the men taking the drug. Given that no proven,
documented therapeutic approach of postfinasteride
syndrome currently exist, it may be worthwhile to

to biochemical action and adverse effects

progesterone

Extrapolating from such findings, it appears

receiving

Finasteride, effects found in both cerebrospinal
fluid and plasma (21). Contrasting with this
biochemical action, finasteride adverse effects are

use hand preference and sexual orientation as
possible predicting conditions for adverse effects so
as to identify prior to therapy those subjects having
a higher chance of developing such effects, should
they receive finasteride (7, 8).
Acknowledgments:

encountered only in a subset of men (39), most

This work was supported by a scientific project
probably due to lateralization processes of the brain of the Ministry of National Education, CNCS(40).
UEFISCDI, project number: PN-II-ID-PCE- 2012Based on several clinical studies, finasteride 4-0409.
appears to decrease sexual function predominantly
in right handed men (7, 8, 39, 40). In contrast, Conclusions
tamoxifen seems to induce adverse reactions

Finasteride adverse effects (encountered during

(sexual side effects and depression) to a greater the drug administration) persist long afterward in
extent in left-handed men (41). In addition, some

patients,

imagistic studies with fRMI suggest that male syndrome

the

(residual

so-called
side

postfinasteride

effects).

Even

so,

sexual pheromones have an evident impact on postfinasteride side effects must be viewed as
homosexual men, activating predominantly the left distinct from finasteride adverse effects, at least due
hemibrain (left angular gyrus, left amygdala, left to two important grounds. First, finasteride adverse
caudate nucleus, etc.). In contrast, yet in some way effects related to the direct presence/ action of the
paralleling

hormone

effects,

female

sexual drug (nausea, postural hypotension, urticaria, rash,
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etc.) cease after finasteride cessation. Second, many symptomatology and the best therapeutic approach
adverse effects that are induced due to indirect (46).
action of finasteride (via hormones and GABA
receptors) persist after finasteride cessation. This References
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